{"id":"https://openalex.org/W2947722113","doi":"https://doi.org/10.1200/jco.2020.38.6_suppl.tps259","title":"VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).","display_name":"VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).","publication_year":2020,"publication_date":"2020-02-19","ids":{"openalex":"https://openalex.org/W2947722113","doi":"https://doi.org/10.1200/jco.2020.38.6_suppl.tps259","mag":"2947722113"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.6_suppl.tps259","doi":"https://doi.org/10.1200/jco.2020.38.6_suppl.tps259","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.6_suppl.tps259","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073246821","display_name":"Oliver A. Sartor","orcid":"https://orcid.org/0000-0002-8777-7343","observed_orcids":["https://orcid.org/0000-0002-8777-7343"]},"institutions":[{"id":"https://openalex.org/I114832834","display_name":"Tulane University","ror":"https://ror.org/04vmvtb21","country_code":"US","type":"education","lineage":["https://openalex.org/I114832834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Oliver Sartor","raw_affiliation_strings":["Tulane Cancer Center, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tulane Cancer Center, New Orleans, LA;","institution_ids":["https://openalex.org/I114832834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017288060","display_name":"Michael J. Morris","orcid":"https://orcid.org/0000-0002-9454-0096","observed_orcids":["https://orcid.org/0000-0002-9454-0096"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Morris","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058543479","display_name":"Richard Messman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I906832008","display_name":"Endocyte (United States)","ror":"https://ror.org/058dk4619","country_code":"US","type":"company","lineage":["https://openalex.org/I906832008"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Messman","raw_affiliation_strings":["Endocyte Inc, West Lafayette, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Endocyte Inc, West Lafayette, IN;","institution_ids":["https://openalex.org/I906832008"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5014284729","display_name":"Bernd Joachim Krause","orcid":"https://orcid.org/0000-0002-2572-4131","observed_orcids":["https://orcid.org/0000-0002-2572-4131"]},"institutions":[{"id":"https://openalex.org/I4210136182","display_name":"Universit\u00e4tsmedizin Rostock","ror":"https://ror.org/04dm1cm79","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210136182"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Bernd J. Krause","raw_affiliation_strings":["Rostock University Medical Center, Rostock, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rostock University Medical Center, Rostock, Germany;","institution_ids":["https://openalex.org/I4210136182"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":44,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"6_suppl","first_page":"TPS259","last_page":"TPS259"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.8560000061988831,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.8560000061988831,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.12280000001192093,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":0.008799999952316284,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/177lu-lu-psma-617","display_name":"177Lu-PSMA-617","score":1.0},{"id":"https://openalex.org/keywords/psma-radioligand-therapy","display_name":"PSMA radioligand therapy","score":0.8289999961853027},{"id":"https://openalex.org/keywords/metastatic-castration-resistant-prostate-cancer","display_name":"metastatic castration-resistant prostate cancer","score":0.9100000262260437},{"id":"https://openalex.org/keywords/prostate-specific-membrane-antigen","display_name":"prostate-specific membrane antigen","score":0.9120000004768372},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6600000262260437},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9990000128746033},{"id":"https://openalex.org/keywords/taxane-pretreatment","display_name":"taxane pretreatment","score":0.5789999961853027}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9290772080421448},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.6789502501487732},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6171091198921204},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.5587288737297058},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5138033032417297},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5068138241767883},{"id":"https://openalex.org/C20417620","wikidata":"https://www.wikidata.org/wiki/Q4140229","display_name":"Glutamate carboxypeptidase II","level":4,"score":0.5029889941215515},{"id":"https://openalex.org/C2776551883","wikidata":"https://www.wikidata.org/wiki/Q1996756","display_name":"Enzalutamide","level":5,"score":0.4815138280391693},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4611819386482239},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.41986072063446045},{"id":"https://openalex.org/C61238886","wikidata":"https://www.wikidata.org/wiki/Q5121689","display_name":"Circulating tumor cell","level":4,"score":0.41437363624572754},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3514534533023834},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3335922658443451},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.32927313446998596},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3116191327571869},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3054749369621277},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.202729731798172},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.20246383547782898}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.6_suppl.tps259","doi":"https://doi.org/10.1200/jco.2020.38.6_suppl.tps259","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.6_suppl.tps259","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4246514338","https://openalex.org/W3172086766","https://openalex.org/W7133190589","https://openalex.org/W3202375713","https://openalex.org/W4402885792","https://openalex.org/W7196948133","https://openalex.org/W4410809398","https://openalex.org/W7206217936","https://openalex.org/W4406716188","https://openalex.org/W2921361010"],"abstract_inverted_index":{"TPS259":[0],"Background:":[1],"The":[2,140],"novel":[3,135],"therapeutic":[4],"drug":[5],"177Lu-PSMA-617":[6,51,61,94],"is":[7,16,83,146,184,199],"a":[8,71,84,131,134,191],"prostate-specific":[9],"membrane":[10],"antigen":[11],"(PSMA)":[12],"targeting":[13],"agent":[14],"that":[15,33,60],"used":[17],"to":[18,89,105,130,147,186,201],"deliver":[19],"radionuclide":[20],"therapy":[21],"for":[22],"the":[23,91,149,216],"treatment":[24],"of":[25,79,93,109,143,153,172,177,195,208,218],"patients":[26,67,74,96,220],"with":[27,68,97,111,190,205],"mCRPC.":[28,99],"Based":[29],"on":[30],"preclinical":[31],"data":[32,58],"demonstrated":[34],"high":[35,48],"PSMA":[36,118,123],"binding":[37],"affinity":[38],"and":[39,47,133,157,170,197,215],"internalization,":[40],"prolonged":[41],"tumor":[42,120],"uptake,":[43],"rapid":[44],"kidney":[45],"clearance,":[46],"tumor-to-background":[49],"ratio,":[50],"proceeded":[52],"into":[53],"clinical":[54,57,64],"development.":[55],"Preliminary":[56],"indicates":[59],"may":[62],"demonstrate":[63],"benefit":[65],"in":[66,70,95,212],"mCRPC":[69],"setting":[72],"where":[73],"had":[75],"no":[76],"clear":[77],"standard":[78,108],"care.":[80],"VISION":[81],"(NCT03511664)":[82],"phase":[85],"3":[86],"study":[87,145],"designed":[88],"assess":[90],"efficacy":[92],"PSMA-positive":[98],"Methods:":[100],"Patients":[101],"were":[102],"randomized":[103],"2:1":[104],"receive":[106],"best":[107],"care":[110],"or":[112],"without":[113],"177Lu-PSMA-617.":[114],"Eligibility":[115],"criteria":[116],"were:":[117],"expressing":[119],"assessed":[121],"by":[122],"positron":[124],"emission":[125],"tomography":[126],"imaging;":[127],"prior":[128],"exposure":[129],"taxane":[132],"androgen":[136],"axis":[137],"inhibitor":[138],"(NAAI).":[139],"primary":[141],"objective":[142],"this":[144],"compare":[148],"two":[150],"alternative":[151],"endpoints":[152],"progression-free":[154],"survival":[155,159],"(rPFS)":[156],"overall":[158],"(OS).":[160],"Stratification":[161],"factors":[162],"include":[163],"lactate":[164],"dehydrogenase,":[165],"liver":[166],"metastasis,":[167],"ECOG":[168],"PS,":[169],"use":[171],"an":[173,206],"NAAI":[174],"at":[175],"time":[176],"randomization.":[178],"On":[179],"active":[180],"treatment,":[181],"median":[182],"OS":[183],"assumed":[185,200],"be":[187,202],"13.7":[188],"months":[189,204],"hazard":[192],"ratio":[193],"(HR)":[194],"0.7306,":[196],"rPFS":[198],"6":[203],"HR":[207],"0.67.":[209],"Enrollment":[210],"began":[211],"June":[213],"2018":[214],"target":[217],"814":[219],"has":[221],"been":[222],"reached.":[223],"Clinical":[224],"trial":[225],"information:":[226],"NCT03511664.":[227]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":18},{"year":2020,"cited_by_count":8},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2019-06-07T00:00:00"}